In Vivo Study on the Pharmacological Interactions between a Chinese Herbal Formula ELP and Antiresorptive Drugs to Counteract Osteoporosis

Figure 6

Effects of different combinations of raloxifene-related treatment in serum osteocalcin levels and excretory DPD levels after 8 weeks. Bars represent the mean ± SEM for each treatment group (𝑛=8 per group). Significant difference: *𝑃<0.05; **𝑃<0.01; ***𝑃<0.001 for difference from OVX group without treatment at the corresponding time point. ^#𝑃<0.05 for difference from corresponding raloxifene group (at the same dosage) without ELP cotreatment.

(a)

(b)